All articles tagged with #danaher
Danaher will acquire Masimo for $9.9 billion, paying $180 per share and a 38.3% premium to Masimo's last close, to broaden its diagnostics portfolio with Masimo's non-invasive monitoring devices; the deal is expected to close by the second half of 2026, Masimo shares jumped while Danaher's fell on the news.
Danaher will acquire Masimo for $180 per share in cash, valuing the deal at about $9.9 billion. The boards have approved the transaction, Masimo will become a standalone business unit and brand within Danaher’s Diagnostics segment, and the deal is expected to close in the second half of 2026 subject to regulatory approvals and other customary closing conditions.
Danaher announced a definitive agreement to acquire Masimo for $180 per share in cash, valuing Masimo at about $9.9 billion including debt and net cash. The deal, which translates to roughly 18x 2027 EBITDA (or 15x with expected synergies), would make Masimo a standalone operating company within Danaher’s Diagnostics segment. Masimo is expected to be accretive to adjusted diluted EPS by $0.15–$0.20 in the first full year and about $0.70 in year five, with long-term high-single-digit core revenue growth and over $530 million in EBITDA in 2027. Danaher also expects more than $125 million of annual cost synergies and over $50 million of annual revenue synergies by the fifth full year post-close. The transaction is targeted to close in the second half of 2026, subject to regulatory approvals, Masimo shareholder approval, and other customary conditions; financing will come from cash on hand and debt. Advisors named include Citi and Goldman Sachs for Danaher, with Kirkland & Ellis as legal counsel.
Danaher is closing in on a roughly $10 billion deal to acquire Masimo, a leading medical-device maker, signaling a major expansion of its health-technology portfolio.
Danaher reported strong Q3 2025 results with $908 million in net earnings, a 4.5% revenue increase to $6.1 billion, and an optimistic full-year outlook maintaining adjusted earnings guidance of $7.70-$7.80 per share, driven by growth in bioprocessing and respiratory segments.
Danaher Corporation has announced an agreement to provide Cepheid's Xpert® MTB/RIF Ultra diagnostic test cartridges for tuberculosis (TB) at cost to the Global Fund to Fight AIDS, TB and Malaria and less-developed countries eligible for Cepheid's Global Access Program. By reducing the price of the test cartridge to $7.97, Danaher will earn no profit. The agreement expands the partnership between Cepheid and the Global Fund, aiming to improve access to high-quality TB testing in countries where it is most needed. The Global Fund is the largest provider of financing and programs to combat TB globally.
Danaher has announced its acquisition of biotech company Abcam in a $5.7 billion deal, which has received mixed reactions from investors due to the premium involved.
Danaher Corporation has announced its plans to acquire Abcam plc, a global supplier of protein consumables, for $5.7 billion. Abcam will operate as a standalone company within Danaher's Life Sciences segment, aligning with Danaher's strategy to advance drug discovery and diagnostics. The acquisition is expected to close in mid-2024, subject to regulatory approvals and shareholder approval.
JPMorgan Chase has come to the rescue of First Republic in a deal that has implications for the U.S. banking system. Meanwhile, equity research firm recommends buying Danaher and owning Club stock for the long term.
Danaher, a life sciences and medical diagnostics company, reported a first-quarter earnings beat but lowered its outlook, causing a drop in its stock price. The revised guidance has prompted a reassessment of the investment case for Danaher, with its rating under review and price target lowered.